- Report
- January 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- January 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- April 2025
- 185 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- March 2025
- 180 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- January 2025
- 180 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- November 2024
- 183 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- August 2024
- 180 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- June 2024
- 183 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- July 2024
- 150 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- July 2024
- 100 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- July 2024
- 100 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- January 2025
- 180 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- March 2025
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- November 2024
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- October 2024
- 200 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- March 2025
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- December 2024
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- December 2024
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- August 2024
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- August 2024
- 178 Pages
Global
From €3986EUR$4,450USD£3,398GBP

The Liquid Biopsy market within the Pharmaceuticals industry is a rapidly growing field of research and development. It is a minimally invasive procedure that uses a sample of blood to detect and monitor cancer. It is used to detect cancer at an early stage, to monitor the progression of the disease, and to assess the effectiveness of treatments. Liquid biopsy can also be used to detect genetic mutations associated with cancer, which can help guide treatment decisions.
The Liquid Biopsy market is expected to grow significantly in the coming years due to its potential to improve patient outcomes and reduce healthcare costs. It is also expected to benefit from advances in technology, such as the development of more sensitive and specific tests.
Some companies in the Liquid Biopsy market include Guardant Health, Exact Sciences, Biocept, and Genomic Health. Show Less Read more